> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Fast Track for Compass Biliary Tract Cancer Drug
- URL: https://www.fdaweb.com/fda-fast-track-for-compass-biliary-tract-cancer-drug/
- Published: 2024-04-25T12:00:00.000Z
- Updated: 2026-09-14T14:29:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156846

FDA has granted fast track designation for Compass Therapeutics’ CTX-009 in combination with paclitaxel in a Phase 2 study to treat patients with metastatic or locally advanced biliary tract tumors that have been previously treated. The company [says](https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-receives-fda-fast-track-designation?ref=fdaweb.com) CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways that are critical to angiogenesis and tumor vascularization.